Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
14 patients with osteolytic bone disease due to breast cancer or myeloma, 7 of whom had hypercalcaemia, received oral treatment with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Serum-calcium dropped to low normal values in all 14 patients, accompanied by a decrease in urine calcium and hydroxyproline excretion-rate. The results show that A.P.D. may inhibit tumour-induced osteolysis.
D001862:Bone Resorption / Q000188:drug therapy*; D001943:Breast Neoplasms / Q000150:complications / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D003404:Creatinine / Q000652:urine; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D006934:Hypercalcemia / Q000188:drug therapy / Q000209:etiology; D009101:Multiple Myeloma / Q000150:complications / Q000378:metabolism; D010014:Osteolysis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D011412:Propanolamines / Q000627:therapeutic use
D004164:Diphosphonates; D011412:Propanolamines; D003404:Creatinine; D006909:Hydroxyproline; D002118:Calcium